Rezaei Nima
Division of Genomic Medicine, Royal Hallam shire Hospital, The University of Sheffield, Sheffield, UK.
Int Immunopharmacol. 2006 Jun;6(6):863-9. doi: 10.1016/j.intimp.2006.02.005. Epub 2006 Mar 3.
Innate immune system could recognize the pathogen-associated molecular patterns by pattern-recognition receptors like Toll-like receptor (TLR) and nucleotide-binding oligomerisation domain (NOD) protein. Information regarding the structure and signalling pathways of TLRs and NODs could provide opportunities for new therapeutic approaches to modulate the innate immunity. Therapeutic targeting could be done by prevention of ligand binding to leucine-rich repeats domains of receptors, blocking the interactions between receptors (like Toll/interleukin-1 receptor domains of TLRs) and adaptors in signalling pathways, blocking the enzymes in signalling pathways, and immunostimulation with vaccine adjuvants. These therapeutic approaches could be useful in the treatment of different human diseases like immunological disorders, infections, and cancers. Further research on these receptors and their signalling pathways could help scientists to identify new candidates for therapeutic targeting.
先天性免疫系统可通过Toll样受体（TLR）和核苷酸结合寡聚化结构域（NOD）蛋白等模式识别受体识别病原体相关分子模式。有关TLR和NOD的结构及信号通路的信息可为调节先天性免疫的新治疗方法提供机会。治疗靶点可通过防止配体与受体富含亮氨酸的重复结构域结合、阻断受体（如TLR的Toll/白细胞介素-1受体结构域）与信号通路中衔接蛋白之间的相互作用、阻断信号通路中的酶以及用疫苗佐剂进行免疫刺激来实现。这些治疗方法可能对治疗免疫紊乱、感染和癌症等不同人类疾病有用。对这些受体及其信号通路的进一步研究可帮助科学家识别新的治疗靶点候选物。
